

Please type a plus sign (+) inside this box →

PTO/SB/06A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/634,047
Filing Date	August 4, 2003
First Named Inventor	Roland Maier
Group Art Unit	1624
Examiner Name	Berch, Mark L.
Attorney Docket Number	01/1385

Sheet

1

of

1

Attorney Docket Number

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ^	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ³ (if known)		
	1	2006/0100199	A1	YOSHIKAWA et al.	05-2006
	2	6,784,195		Michael HALE, et al.	08-2004

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ^	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Reference Passages or Relevant Figures Appear T ⁴
		Office ²	Number ⁴	Kind Code ³ (if known)			
	3	WO	2008/017670	A1	BI Int'l GmbH	02-14-2008	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ^	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
	4	JANUVIA; Patient Information; October 2007	
	5	PATANI GEORGE A. ET AL.: "Bioisosterism : A Rational Approach in Drug Design", Chemical Reviews, 1996, Vol. 96, No. 8, pgs. 3147-3176	
	6	ZEJC, Alfred et al; Badania Nad Piperazynowymi Pochodnymi Dwumetyloksantyn; ACTA POLON. PHARM. XXXV. Nr 4, 1976, pgs. 417-421.	
	7	CYGANKIEWICZ, Andrzej et al., "Investigations into the Piperazine Derivatives of Dimethylxanthine.", ACTA POLON. PHARM. [PAPERS OF POLISH PHARMACOLOGY], XXXIX, No. 5, pp. 607-612, 1977	

Examiner Signature	/Mark Berch/ (11/24/2008)	Date Considered	
--------------------	---------------------------	-----------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Unique citation designation number. ³ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MB/